APP Pharmaceuticals, LLC v. Navinta LLC

181 L. Ed. 2d 39, 132 S. Ct. 115, 565 U.S. 825, 2011 U.S. LEXIS 5450, 80 U.S.L.W. 3182
CourtSupreme Court of the United States
DecidedOctober 3, 2011
DocketNo. 10-1502
StatusPublished

This text of 181 L. Ed. 2d 39 (APP Pharmaceuticals, LLC v. Navinta LLC) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
APP Pharmaceuticals, LLC v. Navinta LLC, 181 L. Ed. 2d 39, 132 S. Ct. 115, 565 U.S. 825, 2011 U.S. LEXIS 5450, 80 U.S.L.W. 3182 (U.S. 2011).

Opinion

Petition for writ of certiorari to the United States Court of Appeals for the Federal Circuit denied.

[40]*40Same case below, 625 F.3d 1359.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Abraxis Bioscience, Inc. v. NAVINTA LLC
625 F.3d 1359 (Federal Circuit, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
181 L. Ed. 2d 39, 132 S. Ct. 115, 565 U.S. 825, 2011 U.S. LEXIS 5450, 80 U.S.L.W. 3182, Counsel Stack Legal Research, https://law.counselstack.com/opinion/app-pharmaceuticals-llc-v-navinta-llc-scotus-2011.